Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial.
about
Weekly versus biweekly bortezomib given in patients with indolent non-Hodgkin lymphoma: A meta-analysisPevonedistat, a NEDD8-activating enzyme inhibitor, is active in mantle cell lymphoma and enhances rituximab activity in vivoTreatment challenges in the management of relapsed or refractory non-Hodgkin's lymphoma - novel and emerging therapies.Differential gene expression profiles of PPP2R5C-siRNA-treated malignant T cells.Mitotic catastrophe and cell cycle arrest are alternative cell death pathways executed by bortezomib in rituximab resistant B-cell lymphoma cells
P2860
Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial.
description
2012 nî lūn-bûn
@nan
2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Bortezomib plus rituximab vers ...... of a randomized phase 3 trial.
@ast
Bortezomib plus rituximab vers ...... of a randomized phase 3 trial.
@en
type
label
Bortezomib plus rituximab vers ...... of a randomized phase 3 trial.
@ast
Bortezomib plus rituximab vers ...... of a randomized phase 3 trial.
@en
prefLabel
Bortezomib plus rituximab vers ...... of a randomized phase 3 trial.
@ast
Bortezomib plus rituximab vers ...... of a randomized phase 3 trial.
@en
P2093
P2860
P356
P1476
Bortezomib plus rituximab vers ...... of a randomized phase 3 trial.
@en
P2093
Achiel Van Hoof
Bernardo Garicochea
Bertrand Coiffier
Christopher Enny
Dixie-Lee Esseltine
Dolores Caballero
Eugene Zhu
Huaqing Wang
Nuriet K Khuageva
Panteli Theocharous
P2860
P2888
P356
10.1186/1756-8722-5-67
P577
2012-10-22T00:00:00Z
P5875
P6179
1032106567